
Valitse etikettisi
näkyy suoraan injektiopullossaDapagliflozin (Forxiga)
Medication
- Lähetetään Saksasta
Tilaus
- DHL seurannalla
- Huomaamaton pakkaus
Yhdellä silmäyksellä
Dapagliflozin (Forxiga) lukuina
Tietopankkimme keskeiset luvut. Vedä pistettä käyrää pitkin nähdäksesi, paljonko yhden annoksen jälkeen on laskennallisesti jäljellä.
Koko tietopankkiartikkeliHow long does it stay in the body?
Share left after one dose, calculated with a half-life of ~12.9 hours
Simplified model without an absorption phase, half-life from the TPD lexicon.
Half-life
about12.9hours
- Class
- SGLT2 inhibitorgliflozin, selective
- Use
- Oral1x daily
- Sizes
- 10 mg1 size in the shop
What studies show
All 6 sources in the lexicon- McMurray et al., NEJM, 2019
Dapagliflozin and cardiovascular outcomes in type 2 diabetes (DECLARE-TIMI 58) (opens in a new tab)
Wiviott et al., NEJM, 2019Euglycemic diabetic ketoacidosis as a complication of SGLT2 inhibition (opens in a new tab)
Peters et al., Diabetes Care, 2015
Arvostelut
Mitä asiakkaat sanovat
Vain todelliset tilaukset, joissa oli Dapagliflozin (Forxiga).
Kaikki arvostelutTuotteelle Dapagliflozin (Forxiga) ei ole vielä laboratorioanalyysia. Äänestä sitäTestauta itse, me maksamme puoletKaikki laboratorioanalyysit
Tietoa
Kaikki aiheesta Dapagliflozin (Forxiga)
Tarkemmat tiedot tulossa pian.
How does dapagliflozin work?
It blocks the transporter SGLT2 in the kidney, which brings filtered sugar back into the blood. The sugar then leaves with the urine without insulin being needed. Breakdown runs mainly via the enzyme UGT1A9 to an inactive metabolite.
Does it help without diabetes?
In the trials on heart failure and chronic kidney disease the effect was similar with and without diabetes. With reduced pumping the risk of worsening or cardiac death fell by 26 percent.
What did the kidney trial show?
Among 4,304 participants 9.2 percent on dapagliflozin and 14.5 percent on placebo had an event (halved kidney function, kidney failure or death). 19 had to be treated to prevent one. The trial was therefore stopped early.
What is euglycaemic ketoacidosis?
Acidosis from ketones with nearly normal blood sugar. Because sugar does not rise much, it was recognised late in a case series. The authors advise checking ketones in case of nausea, vomiting or malaise. In the large diabetes trial it occurred in 0.3 versus 0.1 percent.
Does it lower heart attacks and strokes?
Not clearly in the diabetes trial with 17,160 patients: 8.8 versus 9.4 percent major cardiovascular events. Hospital stays for heart failure and kidney events did fall clearly.
Which side effects are known?
Serious genital infections or those leading to a stop occurred in 0.9 versus 0.1 percent, ketoacidosis in 0.3 versus 0.1 percent. In the heart failure trials volume depletion, kidney problems and low blood sugar were not more common than on placebo.
Liittyvät
Samankaltaiset tuotteet
Telmisartan
Lääkkeet · Sydän ja verisuonet Sydän ja verisuonet
2 kokoa
Laboratoriotestattu
Ivermectin
Lääkkeet · Vatsa ja maksa Vatsa ja maksa
1 koko
Fenbendazol
Lääkkeet · Vatsa ja maksa Vatsa ja maksa
1 koko
Prednisone
Lääkkeet · Vatsa ja maksa Vatsa ja maksa
1 koko
Dapagliflozin (Forxiga)